EP
AIMT

Elkfork Partners’s Aimmune Therapeutics AIMT Stock Holding History

Elkfork Partners’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-660
Closed -$16K – 1054
2018
Q4 		$16K Buy
+660
New +$17.1K ﹤0.01% 993
2018
Q3 		– Sell
-946
Closed -$25K – 1032
2018
Q2 		$25K Buy
+946
New +$29K ﹤0.01% 992

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Elkfork Partners's AIMT Position: Q1 2019 in Review

Elkfork Partners sold out of Aimmune Therapeutics (AIMT) in Q1 2019, closing a stake of 660 shares — an estimated $16K sold.

Elkfork Partners first reported a position in AIMT in Q2 2018 and held it in 2 quarters. The position peaked at $25K in Q2 2018. 125 funds tracked by Wall St. Rank hold AIMT as of Q1 2019.

  • Elkfork Partners reported no remaining Aimmune Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Elkfork Partners sold 660 Aimmune Therapeutics shares in Q1 2019, an estimated $16K.
  • Elkfork Partners first reported a position in Aimmune Therapeutics in Q2 2018 and held it in 2 quarters.
  • Elkfork Partners's Aimmune Therapeutics position peaked at $25K in Q2 2018.
  • 125 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q1 2019.

Based on Elkfork Partners's 13F filing for Q1 2019, filed 13 May 2019.